Meredith A Brisco1, Susan J Cheng2, Olga Laur2, Alexander J Kula2, Jeffrey M Testani3. 1. Cardiology Division, Department of Medicine, Medical University of South Carolina, Charleston, S.C., USA. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn., USA. 3. Program of Applied Translational Research, Yale University School of Medicine, New Haven, Conn., USA ; Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn., USA.
Abstract
BACKGROUND: In decompensated heart failure (HF), reversible renal dysfunction (RD) is more frequently observed in patients with mild liver dysfunction likely due to the shared pathophysiologic factors involved. The objective of this study was to determine if these findings also apply to stable HF outpatients. METHODS: Patients in the Beta-Blocker Evaluation of Survival Trial (BEST) were studied. Improvement in renal function (IRF) was defined as a 20% improvement in the estimated glomerular filtration rate from baseline to 3 months. RESULTS: Elevated bilirubin (BIL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly associated with signs of congestion or poor perfusion. IRF occurred in 12.0% of all patients and was more common in those with elevated BIL (OR = 1.5, p = 0.003), ALT (OR = 1.4, p = 0.01), and AST (OR = 1.4, p = 0.01). In a model containing all 3 liver parameters and baseline characteristics, including markers of congestion/poor perfusion, BIL (OR = 1.6, p = 0.001) and ALT (OR = 1.7, p < 0.001) were independently associated with IRF. CONCLUSIONS: Biochemical evidence of mild liver dysfunction is significantly associated with IRF in stable HF outpatients. Given the widespread availability and low cost of these markers, additional research is necessary to determine the utility of these parameters in identifying patients with reversible RD who may benefit from cardiorenal interventions.
BACKGROUND: In decompensated heart failure (HF), reversible renal dysfunction (RD) is more frequently observed in patients with mild liver dysfunction likely due to the shared pathophysiologic factors involved. The objective of this study was to determine if these findings also apply to stable HF outpatients. METHODS:Patients in the Beta-Blocker Evaluation of Survival Trial (BEST) were studied. Improvement in renal function (IRF) was defined as a 20% improvement in the estimated glomerular filtration rate from baseline to 3 months. RESULTS: Elevated bilirubin (BIL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly associated with signs of congestion or poor perfusion. IRF occurred in 12.0% of all patients and was more common in those with elevated BIL (OR = 1.5, p = 0.003), ALT (OR = 1.4, p = 0.01), and AST (OR = 1.4, p = 0.01). In a model containing all 3 liver parameters and baseline characteristics, including markers of congestion/poor perfusion, BIL (OR = 1.6, p = 0.001) and ALT (OR = 1.7, p < 0.001) were independently associated with IRF. CONCLUSIONS: Biochemical evidence of mild liver dysfunction is significantly associated with IRF in stable HF outpatients. Given the widespread availability and low cost of these markers, additional research is necessary to determine the utility of these parameters in identifying patients with reversible RD who may benefit from cardiorenal interventions.
Authors: Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori Journal: N Engl J Med Date: 2001-05-31 Impact factor: 91.245
Authors: C M O'Connor; R C Starling; A F Hernandez; P W Armstrong; K Dickstein; V Hasselblad; G M Heizer; M Komajda; B M Massie; J J V McMurray; M S Nieminen; C J Reist; J L Rouleau; K Swedberg; K F Adams; S D Anker; D Atar; A Battler; R Botero; N R Bohidar; J Butler; N Clausell; R Corbalán; M R Costanzo; U Dahlstrom; L I Deckelbaum; R Diaz; M E Dunlap; J A Ezekowitz; D Feldman; G M Felker; G C Fonarow; D Gennevois; S S Gottlieb; J A Hill; J E Hollander; J G Howlett; M P Hudson; R D Kociol; H Krum; A Laucevicius; W C Levy; G F Méndez; M Metra; S Mittal; B-H Oh; N L Pereira; P Ponikowski; W H W Tang; W H Wilson; S Tanomsup; J R Teerlink; F Triposkiadis; R W Troughton; A A Voors; D J Whellan; F Zannad; R M Califf Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor Journal: N Engl J Med Date: 2011-03-03 Impact factor: 91.245
Authors: V M van Deursen; K Damman; H L Hillege; A P van Beek; D J van Veldhuisen; A A Voors Journal: J Card Fail Date: 2009-09-26 Impact factor: 5.712
Authors: Meredith A Brisco; Steven G Coca; Jennifer Chen; Anjali Tiku Owens; Brian D McCauley; Stephen E Kimmel; Jeffrey M Testani Journal: Circ Heart Fail Date: 2013-01-16 Impact factor: 8.790
Authors: Meredith A Brisco; Brian D McCauley; Jennifer Chen; Chirag R Parikh; Jeffrey M Testani Journal: J Card Fail Date: 2013-10-17 Impact factor: 5.712
Authors: Horng H Chen; Kevin J Anstrom; Michael M Givertz; Lynne W Stevenson; Marc J Semigran; Steven R Goldsmith; Bradley A Bart; David A Bull; Josef Stehlik; Martin M LeWinter; Marvin A Konstam; Gordon S Huggins; Jean L Rouleau; Eileen O'Meara; W H Wilson Tang; Randall C Starling; Javed Butler; Anita Deswal; G Michael Felker; Christopher M O'Connor; Raphael E Bonita; Kenneth B Margulies; Thomas P Cappola; Elizabeth O Ofili; Douglas L Mann; Víctor G Dávila-Román; Steven E McNulty; Barry A Borlaug; Eric J Velazquez; Kerry L Lee; Monica R Shah; Adrian F Hernandez; Eugene Braunwald; Margaret M Redfield Journal: JAMA Date: 2013-12-18 Impact factor: 56.272